Xenon Pharmaceuticals (XENE) Non Operating Investment Income (2021 - 2022)

Xenon Pharmaceuticals (XENE) reported Non Operating Investment Income of -$1.3 million for Q2 2022, down 7476.47% year-over-year from $17460.9 in Q2 2021, and up 61.69% quarter-over-quarter from -$3.4 million in Q1 2022.

Xenon Pharmaceuticals (XENE) Non Operating Investment Income (2021 - 2022) Analysis & Trends

Xenon Pharmaceuticals (XENE) has 2 years of Non Operating Investment Income data on file, last reported at -$1.3 million in Q2 2022.

  • Non Operating Investment Income for Q2 2022 came in at -$1.3 million, down 7476.47% year-over-year; the trailing twelve-month figure through Jun 2022 was -$4.7 million (changed N/A YoY), and the FY2021 annual result was -$719000.0, down 18075.0% from the prior year.
  • Non Operating Investment Income advanced to -$1.3 million in Q2 2022 per XENE's latest filing, from -$3.4 million in the prior quarter.
  • Over five years, Non Operating Investment Income peaked at -$17000.0 in Q2 2021 and troughed at -$3.4 million in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Investment Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 235,807.00
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 230,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Xenon Pharmaceuticals 4.61 Bn 4.61 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2022 -1.29 Mn
Jun 30, 2022 -1.29 Mn
Mar 31, 2022 -3.36 Mn
Mar 31, 2022 -3.36 Mn
Jun 30, 2021 -17,000.00
Jun 30, 2021 -17,000.00
Mar 31, 2021 -74,000.00
Mar 31, 2021 -74,000.00